Tuesday, November 25, 2008

2008 Quantum's technology platform update and software releases

It has been an exciting year here in Quantum Pharmaceuticals, another great year for our highly effective small molecule drug discovery and ADMET platform development. Our work is firmly based in basic science: QUANTUM science team developed a vector field theory of water capable of describing numerous anomalous thermodynamic and dielectric of water, as well as interactions of biomolecules in aqueous environments (arXiv:0808.0991).

The progress in our understanding of biomolecules interactions led to further accuracy improvements in our major calculation routines (IC50, solvation energy, etc.). Speed increase and sophistication of the models employed in our simulations provided better ways for false positive elimination. Direct application of our software brought up novel inhibitors of HIV integrase and gp120 proteins, human neutrophyle elastase (HNE) (see collaborations). Massive computations made using Amazon EC2 computing platform let us develop new and refind existing ADMET models (see drug absorbtion prediction (arXiv:0810.2617) as an example).

All the scientific advances are plugged in and available through the following releases of Quantum sofware (sold separately and in packages at discount prices):

q-TOX - enables researches to compute toxic effects of chemicals solely from their molecular structure (LD50, MRDD, side effects) . The robust model is based on completely new approaches. While there are numerous commercially available toxicity prediction software, none offers the depth, scope and precision comparing to q-TOX. The paradigm in the q-TOX approach is based on the premise that biological activity results from the capacity of small molecules to modulate the activity of the proteome.

q-Mol - calculates such physicochemical parameters as Solubility in H2O (g/l); Solubility in DMSO (g/l); LogP, water/octanol; Mol weight; H-bond donors; H-bond acceptors; The number of rotatable bonds;Lipinski-rule-of-5.

q-ADME - For the first time we identified proteins, binding to which correlates well with FA and T1/2. This enabled us to simulate the active component of the ADME properties that has been the heel of Achilles for existing computational approaches still. The software predicts the following properties: Drug half-life (T1/2); Fraction of oral dose absorbed (FA); Caco-2 permeability; Volume of distribution (VD); Octanol/water distribution coefficient (LogP)

q-hERG - a unique and innovative software, which allows you to predict from a molecule structures of compounds their inhibition constants (IC50) for hERG channels.

q-Albumin software takes a molecular structure and calculates HSA binding constant by docking the molecule to both of the HSA active sites (Sudlow site I and Sudlow site II).

Monday, November 3, 2008

5th of November talk@MIPT Interdisciplinary Seminar "Water as a ferroelectric: anomalous properties, long range order and interactions of nano-par....

Moscow Instutite of Physics and Tehcnology, November 5th, 2008. "Water as a ferroelectric: anomalous properties, long range order and interactions of nano-particles in solution" (in russian)



The presentation will be held in room 202НК, 18:35 (read full announcement here).

Tuesday, October 28, 2008

Quantum Pharmaceuticals enters collaboration with Children's Cancer Institute Australia



Moscow, October, 28 2008

Quantum Pharmaceuticals announce drug discovery collaboration with Children's Cancer Institute Australia's (CCIA). Under the terms of the agreement Quantum Pharmaceuticals gets access to CCIA in-house disease target data. Quantum Pharmaceuticals will contribute its technological breakthroughs and expertise in small molecule drug discovery to feed the portfolio of CCIA with new drug candidates. CCIA is to further develop the discovered inhibitors. The targets and financial terms were not disclosed.

About Quantum Pharmaceuticals

Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.

About CCIA

Children's Cancer Institute Australia's (CCIA) vision is to save the lives of all children with cancer and eliminate their suffering.Our mission is to be a leader in preventing cancer, to find new ways of curing cancer in children through world-class research, to ensure the best possible quality of life for these children and their families, to share the vision with others and to increase awareness, participation and funding.

Quantum Pharmaceuticals collaborates with University of Pittsburgh on HIV drug discovery.


Moscow, October, 20 2008

Quantum Pharmaceuticals and University of Pittsburgh announced a drug discovery collaboration in HIV sphere.
Under the terms of agreement Quantum Pharmaceuticals gets access to the target data from University of Pittsburgh. Quantum Pharmaceuticals will apply its industry leading computational technology to discover novel small molecule inhibitors for this target. The University is to provide biological expertise and further develop the discovered inhibitors. The financial terms of the deal were not disclosed.
About Quantum Pharmaceuticals
Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.
About University
of Pittsburgh
Founded in 1787 the University
of Pittsburgh has evolved into an internationally recognized center of learning and research. The University’s 12,000 employees, including 3,800 full-time faculty members, serve about 34,000 students through the programs of 15 undergraduate, graduate, and professional schools.

Friday, October 10, 2008

q-hERG: QUANTUM's innovative approach to hERG binding calculations is updated to v 2.0

Quantum Pharmaceuticals, the owner of this blog, is proud to release version 2.0 of its innovativ HERG protein binding prediction software.



QUANTUM hERG (q-hERG) screening assays is a unique and innovative computational approach, which allows you to predict from a molecule structures of compounds their inhibition constants (IC50) for hERG channels.

Wednesday, October 8, 2008

Making a good water model: Molecules do conformationally change when cross from a gas to water solution

Solvation energy calculation is absolutely crucial for a successful binding free energy (IC50) determination. Quantum Pharmaceuticals develops aqueous solvation models and tests them against available experimental data to validate the theoretical approaches.

The graph on the left represents two types of solvation energy calculations compared with experiments. The first series (small circles) are the energy differences on solvation for a set of molecules without conformational changes taken into account. The second set (large squares) is obtained after a single optimization run.

The correlation with the experiment clearly improves after conformational changes calculations. Apparently this does not only mean that the model is good, it also means that the molecules do change structure when inserted into water from the gas phase.

Thursday, September 25, 2008

From Biological Spectra (multiple protein binding data) to pharmacological profiling!

An ideal drug cures a decease and does not kill a patient (or even lab animals in the course of preclinical testing). Usual drug discovery paradigm is based on studying a compound's properties against a specific, normally decease-related (protein) target. The ability of a compound to bind (inhibit) a specific target is called efficacy.

Even if the efficacy is good, another important property of a compound is its toxicity. Toxicity is related to the compound physical properties, such as solubility etc, as well by its ability to bind to and hence inhibit various vital human proteins (and may be even DNA and RNA).

Common sense suggests that an ideal compound binds its specific drug related target and does not bind to anything else. Anything in between is toxic, at least to a some extent. For example, most of important properties utilize ATP molecules, which means that human body contains a lot of ATP-bindig proteins. If you make a drug attacking an ATP-binding site of a "bad" protein, most probably, a lot of "good" and useful proteins will be also affected. In that case your compound should be toxic. This is indeed the case for many cancer drugs attacking ATP-binding sites of kinases.

The latter statement is the foundation of our approach. Although it's quite conceptually simple, it's useless unless it can be supplemented by a meaningful mathematical model. Let us dwell into some more details to see how the whole thing can be made working.

Let us overview important properties of a drug candidate. First there is a bunch of physical properties, such as solubility, differential solubility, LogP (namely the difference between water and lipid solubility) etc. These quantities are easy to measure, are of direct physical meaning and can be pretty easily calculated (with or without QUANTUM software).

Another set of characteristics defines a compound ability to penetrate through cell membranes and its biochemical in liver. These are quantities deturmining bioavailability, half life, volume of distribution etc. None of such quantities can be evaluated using the simple physical properties alone. For example, drug absorbtion depends on the molecule interaction with proteins actively transporting the molecules through the cell membranes.

The bottom line: bioavailability and other quantities require understanding of a compound binding properties to a selected number of proteins participating in a compound transport and metabolism.

So the conclusion is that IF YOU KNOW WHICH PROTEINS ARE IMPORTANT, AND IF YOU CAN CALCULATE HOW YOUR COMPOUND BINDS TO THEM, YOU KNOW THE COMPOUND PHARMACOLOGICAL AND TOXICOLOGICAL PROPERTIES

Now the only problem how to identify those "important" proteins.

Fortunately, there are thousands of molecules with known properties. What we can do is the following:

- take a molecule
- calculate its binding to any human protein with known 3d structure
- use the obtained binding affinities (numbers) as a molecule's binding profile fingerprint (the Biological Spectrum), characterizing the ability of the molecule to interact with the whole human proteome

Now assume we know such Biological Spectra for 1000s molecules with well known properties. This means we can now datamine the fingerprints->known properites relations. The basic premise is, of course, that the molecules with similar fingerprints have similar properties.

We have a number of proofs of such technology working. The most recent one is the prediction of active transport drug absorption properties for drug like molecues based on the binding data against human brain hexokinase type I-related protein. We prove that the binding energy of a compound against the protein may serve to distinguish between the passively and actively transported molecules and even help to calculated the drug absorbtion quantitatevely.